ClinicalTrials.gg
Sign In
Status unknownNCT01023971MAFATUpdated Dec 2, 2009

Macular Function During Anti-VEGF Treatment

An observational study in Age Related Macular Degeneration, sponsored by Royal Liverpool University Hospital. Status unknown at 1 site in United Kingdom. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2009-12-02.

Sponsored by Royal Liverpool University Hospital · Observational

The sponsor has not verified this record recently (last verified Dec 2009), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
50 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine the changes in macular function during anti-VEGF treatment for neovascular age-related macular degeneration.

Read the detailed description

Macular function will be investigated using visual acuity, contrast sensitivity, mfERG and microperimetry.

02

Conditions studied

  • Age Related Macular Degeneration
03

In context

Macular Degeneration

1,490 studies on the registry are indexed under Macular Degeneration; 208 are open to participants now.

This study's planned enrollment of 40 is below the median of 106 across 427 observational studies indexed under Macular Degeneration.

Browse Macular Degeneration studies →

Lead sponsor

Royal Liverpool University Hospital is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

AMD clinic

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Neovascular AMD in first or second eyes
  • angiographic signs of active subfoveal or juxtafoveal choroidal neovascularization (CNV)
  • BCVA ≥35 ETDRS letters

Exclusion criteria

Exclusion Criteria:

  • Spherical equivalent ≥ ± 6 D
  • Previous treatments for CNV in the studied eye
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)

Groups and cohorts

  • Group A

    Patients investigated with mfERG and MP-1

  • Group B

    Patients investigated by Laser Doppler Flowmetry

06

What researchers measure

Primary outcomes

  1. mfERG central ring amplitude density

    Time frame: 12 months

Secondary outcomes

  1. Mean retinal sensitivity (dB) in three concentric rings (4°, 8° & 12°)

    Time frame: 12 months

  2. Choroidal blood flow (ChBFlow) at fovea and at optic nerve head

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • Clinical Eye Research Centre
    Liverpool, L7 8XP, United Kingdom
    • Simon P HARDING, FRCOphth, MD · Contact · S.P.Harding@liverpool.ac.uk
    • SIMON P HARDING, FRCOphth, MD · Principal investigator
    • CLAUDIO S CAMPA, MD,PhD · Sub investigator
    Recruiting
08

References and documents

Publications

  • Campa C, Hagan R, Sahni JN, Brown MC, Beare NA, Heimann H, Harding SP. Early multifocal electroretinogram findings during intravitreal ranibizumab treatment for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011 Jun 1;52(6):3446-51. doi: 10.1167/iovs.10-6588. PubMed 21357390 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 2, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01023971
Lead sponsor
Royal Liverpool University Hospital
First posted
Dec 2, 2009
Start date
Jan 2009
Last update
Dec 2, 2009

Study contacts

Simon P Harding, FRCOphth, MD
Contact
S.P.Harding@liverpool.ac.uk
+44 0151 706 ext. 3966
Claudio S Campa, MD, PhD
Contact
Claudio.Campa@rlbuht.nhs.uk
+44 0151 706 ext. 3939
Simon P HARDING, FRCOphth, MD
principal investigator · University of Liverpool

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Macular Degeneration →

Other studies from this sponsor

Royal Liverpool University Hospital

Start the discussion